Literature DB >> 10534152

Prospective study of HTLV-I infection in an initially asymptomatic cohort.

G P Taylor1, J H Tosswill, E Matutes, S Daenke, S Hall, B J Bain, R Davis, D Thomas, M Rossor, C R Bangham, J N Weber.   

Abstract

A prospective clinical study of 20 initially asymptomatic HTLV-I-seropositive carriers was commenced in 1991 to determine the natural history of the infection in relation to HTLV-I proviral load, immune responses, and lymphocyte phenotype. Proviral load varied widely between carriers but was relatively constant within an individual over time. The lymphocyte phenotype and prevalence of activated lymphocytes were not predictive of disease and the magnitude of the cytotoxic T-lymphocyte response to HTLV-I was independent of proviral load. Incident conditions, some related to HTLV-I infection, including a case of HTLV-I-associated myelopathy (HAM), were documented in 9 carriers. Development of myelopathy and uveitis was associated with high peripheral blood HTLV-I proviral load that predated symptoms. Persistently high proviral load appears to predate the development of HTLV-I-associated inflammation in neuro-ophthalmic tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534152     DOI: 10.1097/00042560-199909010-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  22 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

3.  Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?

Authors:  Marina Lobato Martins; Jacqueline Cronemberger Guimarães; João Gabriel Ribas; Luiz Cláudio Ferreira Romanelli; Anna Bárbara de Freitas Carneiro-Proietti
Journal:  J Neurovirol       Date:  2016-09-27       Impact factor: 2.643

4.  Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons.

Authors:  Iris Castro; Teresa M Giret; Diogo M Magnani; Helen S Maxwell; Oliver Umland; Jessica K Perry; Jerilyn K Pecotte; Kathleen M Brasky; Glen N Barber; Ronald C Desrosiers; David I Watkins
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

5.  Route of primary HTLV-1 infection regulates HTLV-1 distribution in reservoir organs of infected mice.

Authors:  Masakazu Tanaka; Takayuki Nitta; Binlian Sun; Jun-Ichi Fujisawa; Masanao Miwa
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

6.  Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy.

Authors:  G P Taylor; S E Hall; S Navarrete; C A Michie; R Davis; A D Witkover; M Rossor; M A Nowak; P Rudge; E Matutes; C R Bangham; J N Weber
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.

Authors:  I Best; V Adaui; K Verdonck; E González; M Tipismana; D Clark; E Gotuzzo; G Vanham
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 8.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

10.  Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls.

Authors:  M T T Silva; P Mattos; A Alfano; A Q-C Araújo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.